15154 results for "cancer studies using rna-seq"

in 27.12 milliseconds.

• MCCB Breast Cancer Data Access Committee

  Dac EGAC00001000854

• Rectal Cancer Samples Data Access Committee

  Dac EGAC00001001034

• University of Florida Brain Cancer DAC

  Dac EGAC00001001035

• DAC for Familial Breast Cancer study EGAS00001003305

  Dac EGAC00001001087

• OSBREAC (Oslo Breast Cancer Research Consortium)

  Dac EGAC00001001186

• Ewha-Samsumg Lung cancer collaboration DAC

  Dac EGAC00001001237

• Ewha-Samsung Lung cancer collaboration DAC

  Dac EGAC00001001283

• UCL Cancer Institute Data Access Committee

  Dac EGAC00001001360

• Yale Cancer Center Data Access Commitee

  Dac EGAC00001001437

• Lung cancer TRM Data Access Commitee

  Dac EGAC00001001759

• Gene expression and Cancer

  Dac EGAC00001001772

• 4C Endometrial Cancer Data Access Committee

  Dac EGAC00001001956

• University of Calgary Charbonneau Cancer Institute

  Dac EGAC00001002170

• The MITIMM Cancer Data Access Committee

  Dac EGAC00001002268

• EPICC: Evolutionary Predictions in Colorectal Cancer

  Dac EGAC00001002299

• Cancer Sequencing Data Access Committee

  Dac EGAC00001002457

• Cancer Core Europe Data Access Commitee

  Dac EGAC00001002460

• Laboratory of Applied Cancer Genomics team

  Dac EGAC00001002508

• Laboratory of Applied Cancer Genomics team

  Dac EGAC00001002520

• Laboratory of Applied Cancer Genomics team

  Dac EGAC00001002526

• Laboratory of Applied Cancer Genomics team

  Dac EGAC00001002535

• Laboratory of Applied Cancer Genomics team

  Dac EGAC00001002541

• Laboratory of Applied Cancer Genomics team

  Dac EGAC00001002554

• Laboratory of Applied Cancer Genomics team

  Dac EGAC00001002580

• Prostate Cancer Sample Data Access Commitee

  Dac EGAC00001002586

• Laboratory of Applied Cancer Genomics team

  Dac EGAC00001002587

• EPICC: Evolutionary Predictions in Colorectal Cancer

  Dac EGAC00001002592

• Prostate Cancer Sample Data Access Commitee

  Dac EGAC00001002593

• UCL cancer institute data access commitee

  Dac EGAC00001002659

• Salivary gland cancer TSO500 data team

  Dac EGAC00001002668

• INSERM U944 Team Genome and Cancer

  Dac EGAC00001002976

• Cancer Team Data Access Committee

  Dac EGAC00001002982

• Ovarian Cancer Data Access Committee

  Dac EGAC00001003014

• Cancer Genomics Project DBA Data Access Committee

  Dac EGAC01000000005

• MESA colorectal cancer data access committee

  Dac EGAC00001002798

• Cancer Epigenetics Group

  Dac EGAC00001003349

• Metastatic Breast Cancer Data Access Committee

  Dac EGAC00001003074

• Genomic characterization of retinoblastoma

  Study EGAS00001005248

• Soft tissue sarcoma sequencing data

  Study EGAS00001006356

• HGSOC organoid sequencing study

  Study EGAS00001007189

• early-Duodenal Cancer sequencing study

  ...

  Study EGAS00001006357

• Primary Cytotoxic T Cell Lymphomas Harbor Recurrent Targetable Alterations in the JAK-STAT Pathway

  Cytotoxic cutaneous T cell lymphomas (CTCLs) are uncommon but highly aggressive cancers of skin-homing cytotoxic T cells. These include the established World Health Organization (WHO) entity primary cutaneous gamma delta T cell lymphomas (PCGDTLs), the provisional WHO entity primary cutaneous CD8+ aggressive epidermotropic T cell lymphoma (PCAETCL), and samples that do not currently fit into a WHO category, referred to as cytotoxic CTCL-NOS (not otherwise specified). In this study, 35 CTCL cases were examined, and 9 PCAETCL cases were confirmed by CD8 expression and full-thickness epidermotropism. Whole genome sequencing (WGS) and bulk RNA sequencing were performed on these samples.  

  Study phs002499

• Single-cell spatiotranscriptomic dissection of ex vivo human heart right atrial appendage and pericardial fluid in ischemic heart disease and heart failure

  We use cardiac and pericardial fluid biopsies collected during open-heart surgery in control, ischemic heart disease, heart failure, and myocardial infarction context. For each sample, single-nuclei RNA sequencing experiment is performed. We also perform spatial transcriptomics on the heart samples. We annotate the cells in major cell types, in addition to subtypes annotation of vascular and immune cells. The disease annotation enables us to reveal substantial differences in gene expression at the cell subpopulation levels. Our results demonstrate the importance of high-resolution cellular type/state mapping in the elucidation of human cardiovascular disease pathogenesis.

  Study EGAS50000000653

• Assessing Individual Head and Neck Squamous Cell Carcinoma Patient Response to Therapy Through Integration of Functional and Genomic Data

  This study combines RNA sequencing (RNASeq), whole exome sequencing (WES), reverse phase protein array (RPPA) and copy number variation (CNV) data, along with a custom high throughput inhibitor assay to characterize tumor cells from patients with head and neck squamous cell carcinoma (HNSCC), in order to identify potential therapy targets on an individual patient basis. The data that will be available through dbGaP include the RNASeq, WES, RPPA and array CNV data for the tumor and matched normal samples. This study represents a proof-of-concept. No treatments were administered to patients as part of this study.

  Study phs003456

• Molecular phenotyping of MCA/ID patients to improve diagnosis

  De novo structural variants are frequently identified in individuals with neurodevelopmental disorders, but the genes driving their phenotypes are often unknown. In this study we performed Whole Genome Sequencing, RNA-sequencing and ATAC-sequencing on samples of 51 patients with intellectual disability and/or multiple congenital anomalies and their biological parents (when available). The goals of the study were to gain more insights in the molecular consequences of (complex) genomic rearrangements and to improve the genetic diagnosis of patients carrying such rearrangements. Data is divided in four separate datasets based on type of source material and data access restrictions due to consent.

  Study EGAS00001003489

• Ovarian carcinosarcoma genomics and eribulin response

  Ovarian carcinosarcoma (OCS) is an aggressive and rare tumour type with limited treatment options. OCS is hypothesised to develop via the combination theory, with a single progenitor resulting in carcinomatous and sarcomatous components, or alternatively via the conversion theory, with the sarcomatous component developing from the carcinomatous component through epithelial-to-mesenchymal transition (EMT). In this study, we analysed DNA variants from isolated carcinoma and sarcoma components to show that OCS from 18 women is monoclonal. RNA sequencing indicated the carcinoma components were more mesenchymal when compared with pure epithelial ovarian carcinomas, supporting the conversion theory and suggesting that EMT is important in the formation of these tumours.

  Study EGAS00001006555

• NIBIT-M4 Clinical Trial samples

  Patients (N=14) with unresectable stage III/IV melanoma received escalating doses of guadecitabine 30, 45, or 60 mg/m2/day subcutaneously on days 1 to 5 every 3 weeks, and ipilimumab 3 mg/kg intravenously on day 1 every 3 weeks, starting 1 week after guadecitabine, for four cycles. Patient-wise genome-wide DNA methylation, Whole Exome and RNA sequencing were then performed for samples obtained by surgical removal or fine-needle biopsy at baseline (W0), week 4 (W4) and week 12 (W12) after treatment. For Whole Exome Sequencing profiling, normal matched skin tissue was available only for the first eight patients.

  Study EGAS00001006736

• Methylation-based classification of human mesenchymal chondrosarcoma

  We applied methylome and copy number profiling to a set of 45 well characterized MCS cases to evaluate their potential diagnostic value. Notably, the findings were reproducible also when analysing the round cell and cartilaginous component separately. Furthermore, four outliers were identified by methylome profiling for which the diagnosis had to be revised. Methylome profiling represents a sensitive, specific and reliable tool to support the diagnosis of MCS, particularly if only the round cell component is obtained in a biopsy and the diagnosis is not suspected. It can furthermore aid in confirming the diagnosis in case RNA sequencing for the HEY1::NCOA2 fusion transcript is not available.

  Study EGAS00001007042

• PRADO trial - Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab plus nivolumab in stage III melanoma

  The PRADO trial tested a personalized response-directed treatment approach based on the pathologic response after neoadjuvant ipilimumab plus nivolumab in stage III melanoma patients. In patients achieving a major pathologic response, in their index lymph node (the largest lymph node metastasis at baseline), therapeutic lymph node dissection (TLND) and adjuvant therapy were omitted. Patients with partial response underwent TLND only, whereas patients with pathologic non-response underwent TLND and adjuvant systemic therapy ± synchronous radiotherapy. Biomarker analyses based on baseline RNA sequencing data were performed in order to find features that are associated with major pathologic response.

  Study EGAS00001007601

• Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin’s lymphoma

  Employed single cell RNA sequencing and protein surface marker profiling of serialCAR-T cell samples from patients with non-Hodgkin’s lymphoma (NHL) to reveal CAR-T cell evolution, identify biomarkers of response, and test for evidence of exhaustion inCAR-T cells of poor responders. At the transcriptional and protein levels, we note the evolution of CAR-T cells toward a non-proliferative, highly-differentiated, andexhausted state that is enriched in CAR-T cells of patients with poor response.Furthermore, we identified the checkpoint receptor TIGIT as a novel prognosticbiomarker and potential driver of CAR-T cell exhaustion.

  Study EGAS00001005356